The chipmaker beat Wall Street targets across major financial metrics for the September quarter, driven directly by artificial intelligence technologies. Revenue jumped 45% compared to the prior year, reaching $13.4 billion alongside significant earnings expansion. Furthermore, the company reinforced market confidence by delivering an upbeat financial forecast.
Key points
Tangible revenue growth from artificial intelligence technologies is directly fueling the…: Tangible revenue growth from artificial intelligence technologies is directly fueling the chipmaker's overall business momentum.
Strong earnings and a positive financial forecast helped ease prevailing market concerns…: Strong earnings and a positive financial forecast helped ease prevailing market concerns about AI sector sustainability.
The company's extended trading share price rose following the better-than-expected third-…: The company's extended trading share price rose following the better-than-expected third-quarter financial report.
Sources checked by our analysis pipeline: 1
Earnings Results
Here’s why AMD’s stock is rising — and sending a confident message about the AI trade
The chip maker is showing ‘real’ revenue from AI, shrugging off sustainability concerns and leading to an upbeat forecast
Shares of Advanced Micro Devices were climbing in extended trading Tuesday as investors were encouraged by the company’s third-quarter earnings results — especially against a tough recent trading backdrop for artificial-intelligence-related companies.
AMD AMD saw revenue come in at $13.4 billion for the September quarter, up 45% from a year ago and ahead of the $13.1 billion analysts tracked by FactSet had been looking for. Its adjusted earnings of $2.09 per share also topped estimates for $1.95 and represented growth of 74% year over year.
Surging market valuations fueled by artificial intelligence investments are driving state-backed investors to capitalize on key supply chain assets. Instead of orchestrating broader industry consolidation as originally envisioned, the state fund is positioning a domestic corporate giant to absorb critical photoresist manufacturing capabilities. A formal agreement between the entities could finalize as soon as this month.
The industrial manufacturing giant is confronting massive legal liabilities tied to chemical exposure claims across the country. This significant charge highlights the mounting corporate accountability surrounding historical environmental and health damages. The substantial financial obligation will notably impact the company's bottom line moving forward.
The biopharmaceutical company is advancing a multi-million-pound capital program to upgrade its scientific presence in the United Kingdom. This expansion aims to enhance the organization's existing drug discovery capabilities across critical therapeutic pipelines. The project underscores an ongoing commercial strategy to leverage local scientific talent and regional infrastructure.